Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GLAND.NS
Strong BuyPremium GrowerGland Pharma Limited · Healthcare · India · $5.1B · Avg Vol: $28M/d
88
StockRankGet insider-trade alerts
Q
77
V
24
M
85
P/E (TTM)
44.3x
ROE
9.9%
D/E
0.0x
Dividend %
0.7%
COMPANY DESCRIPTION
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 35.9B | 56.4B | 55.8B | 64.0B | 21.3% | 67.3B | 74.6B | 85.5B | 15.5% |
| EPS (INR) | 47.44 | 46.90 | 42.40 | 62.35 | 9.5% | 68.36 | 79.14 | 95.41 | 23.7% |
| Shares | 164.7M | 164.7M | 164.8M | 164.8M | +0.0% | 165.0M | — | — | — |
| Debt | 44.5M | 3.7B | 3.1B | 2.8B | 299.3% | 2.8B | — | — | — |
| Equity | 79.6B | 87.2B | 91.5B | 103.6B | 9.2% | — | — | — | — |
| Op CF | 3.6B | 10.0B | 9.1B | 10.3B | 41.5% | 10.3B | — | — | — |
| Inv CF | 12.1B | -17.6B | 17.0B | 1.4B | — | — | — | — | — |
| Fin CF | 149.2M | -8.0B | -4.3B | -4.2B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+21.1%
SMA 50SMA 200
Close
$31.82
RSI (14)
77.7
52W High
$31.99
From 52W High
1.0%
SCORE BREAKDOWN
Quality
77
ROIC
13.7%80.2
ROE
9.9%70.1
GP/Assets
31.8%66.6
Op. Margin
21.0%84.2
FCF/Assets
4.3%67.0
Piotroski
999.1
Int. Cover
50.0x89.2
D/E Ratio
0.03x77.1
Current Ratio
4.68x70.0
Value
24
P/E (TTM)
44.3x25.2
EV/EBITDA
26.6x24.0
P/FCF
91.2x16.6
P/B
4.8x30.1
P/S
7.4x31.7
Div Yield
0.7%19.9
Momentum
85
52W High %
99%99.4
RS 6M
87%95.6
SMA 50/200
1.30x93.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+41%49.4
Q Growth
47%73.1
FUNDAMENTALS
Market Cap
$5.1B
P/E (Forward)
31.4x
Gross Margin
59.2%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GLAND.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GLAND.NS | Gland Pharma Limited(you) | $5.1B | 88 | Strong Buy |
| IPCALAB.NS | Ipca Laboratories Limited | $5.3B | 91 | Strong Buy |
| AJANTPHARM.NS | Ajanta Pharma Limited | $4.7B | 79 | Buy |
| ABBOTINDIA.NS | Abbott India Limited | $5.7B | 78 | Buy |
| EMCURE.NS | Emcure Pharmaceuticals Limited | $3.9B | 81 | Strong Buy |
| GLENMARK.NS | Glenmark Pharmaceuticals Limited | $7.4B | 94 | Strong Buy |
| GRANULES.NS | Granules India Limited | $2.3B | 87 | Strong Buy |
| AUROPHARMA.NS | Aurobindo Pharma Limited | $10.3B | 91 | Strong Buy |
| LUPIN.NS | Lupin Limited | $10.2B | 91 | Strong Buy |
| CAPLIPOINT.NS | Caplin Point Laboratories Limited | $2.2B | 86 | Strong Buy |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%